Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Mars to buy pet healthcare provider VCA for $7.7 billion

Published 01/09/2017, 01:00 PM
Updated 01/09/2017, 01:00 PM
© Reuters. Pedigree brand dry dog food is seen at the Safeway store in Wheaton Maryland

(Reuters) - Candy and pet food conglomerate Mars Inc is buying veterinary hospital operator VCA Inc (O:WOOF) for $7.7 billion in a deal that will give the maker of Pedigree pet food an even bigger share of the $4 billion global pet healthcare market.

The deal will help family-owned Mars, better known for candies such as M&Ms and Snickers, add about 800 pet hospitals to its network of more than 900 clinics, which includes the 61-year-old Banfield pet hospital chain.

McLean, Virginia-based Mars is already the biggest pet food company in the world - it held a quarter of the $71.77 billion global pet food market as of 2015 - followed by Nestle SA (S:NESN), the maker of the Purina cat and dog food brand.

Mars and Nestle also hold the mantle of being the No.1 and No.3 confectionary makers in the world, respectively, according to Euromonitor data.

Candy makers have been diversifying their business as calorie-conscious consumers increasingly shun sugary sweets, a trend that has weighed on the $183 billion global confectionery market.

Rival Hershey Co (N:HSY) is also expanding beyond chocolates - it bought Krave, a beef jerky maker, in 2015, while Mondelez International Inc (O:MDLZ) recently introduced Good Thins, its first snack brand in more than a decade.

"While most of Mars Pet is focused on food, the firm had long dabbled in pet healthcare services," Morningstar analyst Debbie Wang wrote in a note.

"Considering that growth in pet healthcare has averaged 7-8 percent over the long term, the addition of VCA would help Mars tap into this appealing market."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Mars said it would offer $93 per share, a premium of 31.4 percent to VCA's Friday closing price. Including debt, the deal is valued at $9.1 billion.

VCA's shares were up 19.8 percent at $90.60 in afternoon trading on Monday. The company, founded in 1986, had annual sales of $2.13 billion in 2015.

Mars, which also owns the BluePearl chain of emergency and specialty veterinary care clinics, had annual pet food sales of $17.80 billion in 2015, according to Euromonitor data.

Morgan Stanley & Co (NYSE:MS). LLC and BDT & Co were Mars' financial advisers, while Skadden, Arps, Slate, Meagher & Flom provided legal advice.

Barclays (LON:BARC) was VCA's financial adviser and Akin Gump Strauss Hauer & Feld LLP and Potter Anderson Corroon LLP were legal advisers.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.